Suppr超能文献

肿瘤分化作为临床分期为T1bN0食管腺癌预后标志物的研究

Tumor Differentiation as a Prognostic Marker in Clinically Staged T1bN0 Esophageal Adenocarcinoma.

作者信息

Margalit Ofer, Shacham-Shmueli Einat, Strauss Gal, Yang Yu-Xiao, Lawrence Yaacov R, Ben Nun Alon, Levy Idan, Reiss Kim A, Golan Talia, Halpern Naama, Aderka Dan, Giantonio Bruce, Mamtani Ronac, Boursi Ben

机构信息

Department of Oncology, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.

Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Tel-Aviv, Israel.

出版信息

Cancer Invest. 2023 Sep;41(8):734-738. doi: 10.1080/07357907.2023.2255907. Epub 2023 Sep 4.

Abstract

Current guidelines recommend that clinically staged T1N0 esophageal cancers are to be referred to surgery or endoscopic resection. Using the National Cancer Database, we identified 733 individuals with clinically staged T1N0 esophageal carcinoma, who underwent upfront surgery and did not receive any prior treatment. We assessed upstaging, which was defined as ≥ T2 disease or positive lymph nodes. Poorly differentiated adenocarcinomas were associated with upstaging, whereas squamous cell carcinomas were not. Specifically, the percentage of upstaging among individuals with clinically staged T1b and poorly differentiated tumor was 33.8%. Therefore, clinically staged T1bN0 poorly differentiated esophageal adenocarcinomas are at high risk for upstaging following surgery.

摘要

当前指南建议,临床分期为T1N0的食管癌应接受手术或内镜切除治疗。利用国家癌症数据库,我们确定了733例临床分期为T1N0的食管癌患者,这些患者接受了初次手术且未接受过任何前期治疗。我们评估了疾病分期上调情况,其定义为疾病进展至≥T2期或出现阳性淋巴结。低分化腺癌与疾病分期上调相关,而鳞状细胞癌则不然。具体而言,临床分期为T1b且肿瘤低分化的患者中疾病分期上调的比例为33.8%。因此,临床分期为T1bN0的低分化食管腺癌患者术后疾病分期上调的风险很高。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验